Compare TCMD & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | ANNX |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 334.1M |
| IPO Year | 2016 | 2020 |
| Metric | TCMD | ANNX |
|---|---|---|
| Price | $29.21 | $5.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $23.25 | $16.50 |
| AVG Volume (30 Days) | 332.5K | ★ 2.9M |
| Earning Date | 02-17-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.83 | N/A |
| P/E Ratio | $38.69 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $1.29 |
| 52 Week High | $30.24 | $5.66 |
| Indicator | TCMD | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 61.69 |
| Support Level | $29.02 | $4.94 |
| Resistance Level | $29.92 | $5.48 |
| Average True Range (ATR) | 0.92 | 0.28 |
| MACD | -0.22 | -0.03 |
| Stochastic Oscillator | 60.90 | 34.93 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.